Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PQ203
- Development stage
- Phase 1
- Lead developer
- ProteinQure
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
PQ203 is a novel peptide-drug conjugate (PDC) developed by ProteinQure for the treatment of triple-negative breast cancer (TNBC). It consists of a sortilin receptor-targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The sortilin receptor (SORT1) is overexpressed in many solid tumors, including TNBC, and represents an innovative target for this aggressive cancer subtype. PQ203 has demonstrated potent efficacy in preclinical models, particularly those resistant to current standards such as sacituzumab govitecan (Trodelvy), and exhibits a favorable safety profile. The drug is designed using ProteinQure’s proprietary AI-driven platform that enables precision targeting and delivery of cytotoxic payloads to tumor cells[1][3][4][6].
- Other names
- PQ203PQ-203PQ 203
02
Targets
SORT1 (Sortilin)
Beyond the preview
Go deeper on PQ203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PQ203.